Home » Topics » Conferences

Conferences
RSS

Vasomax phase III results presented at AUA meeting

June 3, 1998

Nibentan, a potentially safer class III antiarrhythmic agent

June 2, 1998

Venlafaxine: cause of cardiac toxicity identified

June 2, 1998

SR-146131, the most potent CCK-A receptor agonist reported to date

June 2, 1998

NHE inhibition with dietary cariporide proves beneficial in infarct model

June 2, 1998

EMD-96785: a promising cardioprotective agent from Merck KGaA

June 2, 1998

Hemodynamic and electrophysiological effects of S-16257 assessed in dogs

June 2, 1998

ECG and hemodynamic evaluation of dronedarone, a new antiarrhythmic agent

June 1, 1998

JTV-519, a novel cardioprotective agent, and propranolol protect myocardium following SAH

June 1, 1998

Somatostatin analogue TT-232 prevents proliferation of pancreatic cancer

May 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...